Publication:
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Simple item page
dc.contributor.authorGarcia-Delgado, Regina
dc.contributor.authorde Miguel, Dunia
dc.contributor.authorBailen, Alicia
dc.contributor.authorRamon Gonzalez, Jose
dc.contributor.authorBargay Lleonart, Joan
dc.contributor.authorFalantes, Jose F.
dc.contributor.authorAndreu, Rafael
dc.contributor.authorFernando, Ramosh
dc.contributor.authorTormo, Mar
dc.contributor.authorBrunet, Salut
dc.contributor.authorFigueredo, M. A.
dc.contributor.authorCasano, Javier
dc.contributor.authorMedina, Angeles
dc.contributor.authorBadiella, Llorenc
dc.contributor.authorFernandez Jurado, Antonio
dc.contributor.authorSanz, Guillermo
dc.contributor.authorAsociacion Andaluza de Hematologia
dc.date.accessioned2024-07-03T11:09:20Z
dc.date.available2024-07-03T11:09:20Z
dc.date.issued2014-07
dc.description.abstractWe investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.en
dc.description.sponsorshipThe authors received editorial/writing support provided by Christian Geest, PhD, from Excerpta Medica, funded by Celgene Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript.es_ES
dc.format.number7es_ES
dc.format.page744-750es_ES
dc.format.volume38es_ES
dc.identifier.citationGarcia-Delgado R, De Miguel D, Bailen A, Ramon Gonzalez J, Bargay Lleonart J, Falantes JF, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014 Jul;38(7):744-50. Epub 2014 Mar 19.en
dc.identifier.doi10.1016/j.leukres.2014.03.004
dc.identifier.issn0145-2126
dc.identifier.journalLeukemia Researches_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17327
dc.identifier.pubmedID24795069es_ES
dc.identifier.puiL53121904
dc.identifier.scopus2-s2.0-84902116204
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19996
dc.identifier.wos339339400005
dc.language.isoengen
dc.publisherElsevier
dc.relation.publisherversionhttps://dx.doi.org/10.1016/j.leukres.2014.03.004en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial-NoDerivs 3.0 Unported*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/*
dc.subjectAcute myeloid leukemia
dc.subjectAzacitidine
dc.subjectDosing schedules
dc.subjectMyelodysplastic syndromes
dc.subjectOverall survival
dc.subjectSafety
dc.subject.decsModelos de Riesgos Proporcionales*
dc.subject.decsSíndromes Mielodisplásicos*
dc.subject.decsFemenino*
dc.subject.decsMasculino*
dc.subject.decsAzacitidina*
dc.subject.decsHumanos*
dc.subject.decsPersona de Mediana Edad*
dc.subject.decsAnciano*
dc.subject.decsAnciano de 80 o más Años*
dc.subject.decsAntimetabolitos Antineoplásicos*
dc.subject.decsEstudios Retrospectivos*
dc.subject.decsAdulto*
dc.subject.decsLeucemia Mieloide Aguda*
dc.subject.meshAntimetabolites, Antineoplastic*
dc.titleEffectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemiaen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
IBIS - Instituto de Biomedicina de Sevilla (Andalucía)